Axsome Reports Positive Phase 3 Results for Solriamfetol in ADHD Trial

On March 25, 2025, Axsome Therapeutics announced that its Phase 3 FOCUS trial evaluating solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD) met its primary and key secondary endpoints. The company’s investigational use of solriamfetol, currently approved for other indications, demonstrated significant clinical efficacy in adults with ADHD.

The successful outcome of the FOCUS study marks a major milestone for Axsome’s pipeline, potentially expanding the use of solriamfetol into a new therapeutic area. Full details were shared in a press release attached to the company’s 8-K filing with the SEC.